MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1089/dia.2023.0123

Медицинская библиотека · Diabetes technology & therapeutics · 2023

Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.

Cordero Toni L, Dai Zheng, Arrieta Arcelia, Niu Fang, Vella Melissa, Shin John, Rhinehart Andrew S, McVean Jennifer, Lee Scott W, Slover Robert H, Forlenza Gregory P, Shulman Dorothy I, Pop-Busui Rodica, Thrasher James R, Kipnes Mark S, Christiansen Mark P, Buckingham Bruce A, Pihoker Catherine, Sherr Jennifer L, Kaiserman Kevin B, Vigersky Robert A

Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Background

Safety and significant improvement in overall glycated hemoglobin (A1C) and percentage of time spent in (TIR), below (TBR), and above (TAR) glucose range were demonstrated in the pivotal trial of adolescents and adults using the MiniMed™ advanced hybrid closed-loop (AHCL) system with the adjunctive, calibration-required Guardian™ Sensor 3. The present study evaluated early outcomes of continued access study (CAS) participants who transitioned from the pivotal trial investigational system to the approved MiniMed™ 780G system with the non-adjunctive, calibration-free Guardian™ 4 Sensor (MM780G+G4S). Study data were presented alongside those of real-world MM780G+G4S users from Europe, the Middle East, and Africa.

Methods

The CAS participants (N = 109, aged 7-17 years and N = 67, aged >17 years) used the MM780G+G4S for 3 months and data of real-world MM780G+G4S system users (N = 10,204 aged ≤15 years and N = 26,099 aged >15 years) were uploaded from September 22, 2021 to December 02, 2022. At least 10 days of real-world continuous glucose monitoring (CGM) data were required for analyses. Glycemic metrics, delivered insulin and system use/interactions underwent descriptive analyses.

Results

Time in AHCL and CGM use were >90% for all groups. AHCL exits averaged 0.1/day and there were few blood glucose measurements (BGMs) (0.8/day-1.0/day). Adults in both cohorts met most consensus recommendations for glycemic targets. Pediatric groups met recommendations for %TIR and %TBR, although not those for mean glucose variability and %TAR, possibly due to low use of recommended glucose target (100 mg/dL) and active insulin time (2 h) settings (28.4% in the CAS cohort and 9.4% in the real-world cohort). The CAS pediatric and adult A1C were 7.2% ± 0.7% and 6.8% ± 0.7%, respectively, and there were no serious adverse events.

Conclusions

Early clinical use of the MM780G+G4S was safe and involved minimal BGMs and AHCL exits. Consistent with real-world pediatric and adult use, outcomes were associated with achievement of recommended glycemic targets. Clinical Trial Registration number: NCT03959423.

Для цитирования: Cordero Toni L, Dai Zheng, Arrieta Arcelia, Niu Fang, Vella Melissa, Shin John, Rhinehart Andrew S, McVean Jennifer, Lee Scott W, Slover Robert H, Forlenza Gregory P, Shulman Dorothy I, Pop-Busui Rodica, Thrasher James R, Kipnes Mark S, Christiansen Mark P, Buckingham Bruce A, Pihoker Catherine, Sherr Jennifer L, Kaiserman Kevin B, Vigersky Robert A. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.. Diabetes technology & therapeutics. 2023. DOI: 10.1089/dia.2023.0123.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.